Central to its near-term growth plan is the performance of Austedo (deutetrabenazine), approved for Huntington’s disease and tardive dyskinesia, which Teva predicts will bring in $2.5 billion in ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

Considering Teva’s extended-release version of Austedo won a key approval in 2023, ramped-up competition in 2025 is something the team at Evercore ISI had anticipated. Even so, this year’s fir ...

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding freezes, the CEO of Israel's Teva Pharmaceutical Industries said on Monday. "In ...

Also underway, on the flipside, was the decision to ramp up investment in one of Teva’s stable of innovative products, Austedo (deutetrabenazine), a treatment for tardive dyskinesia and chorea ...

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

Revenue in Teva’s U.S. business grew 4% to $8.03 billion driven largely by AUSTEDO and biosimilars but that growth hasn’t been enough to offset other pressures. Gross margin dropped from 55.7% ...

Francis is enthusiastic about Teva's branded drugs, and presented the developments of prominent products. On Austedo ( for tardive dyskinesia and Huntington's disease chorea.), which is already on ...

Teva CEO Richard Francis said that he had not expected such a harsh reaction from the market but he sees a positive side to ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

"I don't think having Teva part of that and having Austedo, a rare disease (treatment), part of that is necessarily the intent of the IRA," he said. Speaking at the news conference on Monday ...